• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

DuPont files NDA for ultrasound agent

Article

DuPont Pharmaceuticals reported this month that it has submitted a new drug application (NDA) to the Food and Drug Administration for Definity, an ultrasound contrast agent formerly known as DMP 115, MRX 115, and Aerosomes. North Billerica, MA-based Du

DuPont Pharmaceuticals reported this month that it has submitted a new drug application (NDA) to the Food and Drug Administration for Definity, an ultrasound contrast agent formerly known as DMP 115, MRX 115, and Aerosomes. North Billerica, MA-based Du Pont hopes Definity will be the first multiuse contrast agent, with applications for both echocardiography and abdominal ultrasound.

For cardiac ultrasound, Definity would enhance ultrasound imaging of cardiac structure and functioning. For abdominal ultrasound, the agent would improve imaging of the liver and kidney. DuPont based its NDA on seven multicenter U.S. clinical trials, which included more than 600 patients.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.